Prediction of Biochemical Recurrence-Free Survival of Prostate Cancer Patients Leveraging Multiple Gene Expression Profiles in Tumor Microenvironment

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Oct 11

PMID 34631510

Citations 9

Authors

Rui Zhou

Yuanfa Feng

Jianheng Ye

Zhaodong Han

Yuxiang Liang

Qingbiao Chen

Xiaoming Xu

Yuhan Huang

Zhenyu Jia

Weide Zhong

Affiliations

Soon will be listed here.

Abstract

Tumor-adjacent normal (TAN) tissues, which constitute tumor microenvironment and are different from healthy tissues, provide critical information at molecular levels that can be used to differentiate aggressive tumors from indolent tumors. In this study, we analyzed 52 TAN samples from the Cancer Genome Atlas (TCGA) prostate cancer patients and developed a 10-gene prognostic model that can accurately predict biochemical recurrence-free survival based on the profiles of these genes in TAN tissues. The predictive ability was validated using TAN samples from an independent cohort. These 10 prognostic genes in tumor microenvironment are different from the prognostic genes detected in tumor tissues, indicating distinct progression-related mechanisms in two tissue types. Bioinformatics analysis showed that the prognostic genes in tumor microenvironment were significantly enriched by p53 signaling pathway, which may represent the crosstalk tunnels between tumor and its microenvironment and pathways involving cell-to-cell contact and paracrine/endocrine signaling. The insight acquired by this study has advanced our knowledge of the potential role of tumor microenvironment in prostate cancer progression.

Citing Articles

Predicting prostate cancer recurrence: Introducing PCRPS, an advanced online web server.

He X, Hu S, Wang C, Yang Y, Li Z, Zeng M Heliyon. 2024; 10(7):e28878.

PMID: 38623253 PMC: 11016622. DOI: 10.1016/j.heliyon.2024.e28878.

Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma.

Dolgalev I, Zhou H, Murrell N, Le H, Sakellaropoulos T, Coudray N Nat Commun. 2023; 14(1):6764.

PMID: 37938580 PMC: 10632519. DOI: 10.1038/s41467-023-42327-x.

Novel Multiparametric Magnetic Resonance Imaging-Based Deep Learning and Clinical Parameter Integration for the Prediction of Long-Term Biochemical Recurrence-Free Survival in Prostate Cancer after Radical Prostatectomy.

Lee H, Kim E, Na I, Kim C, Seo S, Park H Cancers (Basel). 2023; 15(13).

PMID: 37444526 PMC: 10340407. DOI: 10.3390/cancers15133416.

Prediction of prostate cancer biochemical recurrence by using discretization supports the critical contribution of the extra-cellular matrix genes.

Marin L, Casado F Sci Rep. 2023; 13(1):10144.

PMID: 37349324 PMC: 10287745. DOI: 10.1038/s41598-023-35821-1.

Accurate prognosis for localized prostate cancer through coherent voting networks with multi-omic and clinical data.

Pellegrini M Sci Rep. 2023; 13(1):7875.

PMID: 37188913 PMC: 10185505. DOI: 10.1038/s41598-023-35023-9.

References

Jia Z, Rahmatpanah F, Chen X, Lernhardt W, Wang Y, Xia X . Expression changes in the stroma of prostate cancer predict subsequent relapse. PLoS One. 2012; 7(8):e41371. PMC: 3411675. DOI: 10.1371/journal.pone.0041371. View

Nishie M, Suzuki E, Hattori M, Kawaguch K, Kataoka T, Hirata M . Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother. 2020; 70(3):817-830. PMC: 10991185. DOI: 10.1007/s00262-020-02732-3. View

Cuzick J, Swanson G, Fisher G, Brothman A, Berney D, Reid J . Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011; 12(3):245-55. PMC: 3091030. DOI: 10.1016/S1470-2045(10)70295-3. View

Athar A, Fullgrabe A, George N, Iqbal H, Huerta L, Ali A . ArrayExpress update - from bulk to single-cell expression data. Nucleic Acids Res. 2018; 47(D1):D711-D715. PMC: 6323929. DOI: 10.1093/nar/gky964. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Lokman U, Erickson A, Vasarainen H, Rannikko A, Mirtti T . PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance. Eur Urol Focus. 2017; 4(6):867-873. DOI: 10.1016/j.euf.2017.03.004. View

Cooperberg M, Cowan J, Broering J, Carroll P . High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008; 26(3):211-8. PMC: 2948572. DOI: 10.1007/s00345-008-0250-7. View

Ogawa K, Johansson S, Cohen S . Immunohistochemical analysis of uroplakins, urothelial specific proteins, in ovarian Brenner tumors, normal tissues, and benign and neoplastic lesions of the female genital tract. Am J Pathol. 1999; 155(4):1047-50. PMC: 1867018. DOI: 10.1016/S0002-9440(10)65206-6. View

Aran D, Camarda R, Odegaard J, Paik H, Oskotsky B, Krings G . Comprehensive analysis of normal adjacent to tumor transcriptomes. Nat Commun. 2017; 8(1):1077. PMC: 5651823. DOI: 10.1038/s41467-017-01027-z. View

10.

Li R, Wang S, Cui Y, Qu H, Chater J, Zhang L . Extended application of genomic selection to screen multiomics data for prognostic signatures of prostate cancer. Brief Bioinform. 2020; 22(3). DOI: 10.1093/bib/bbaa197. View

11.

Ross-Adams H, Lamb A, Dunning M, Halim S, Lindberg J, Massie C . Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine. 2015; 2(9):1133-44. PMC: 4588396. DOI: 10.1016/j.ebiom.2015.07.017. View

12.

Erho N, Crisan A, Vergara I, Mitra A, Ghadessi M, Buerki C . Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013; 8(6):e66855. PMC: 3691249. DOI: 10.1371/journal.pone.0066855. View

13.

Kamoun A, Cancel-Tassin G, Fromont G, Elarouci N, Armenoult L, Ayadi M . Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Ann Oncol. 2018; 29(8):1814-1821. DOI: 10.1093/annonc/mdy224. View

14.

Wang Y, Yang Z . A Gleason score-related outcome model for human prostate cancer: a comprehensive study based on weighted gene co-expression network analysis. Cancer Cell Int. 2020; 20:159. PMC: 7216484. DOI: 10.1186/s12935-020-01230-x. View

15.

Lai Y, Ye J, Chen J, Zhang L, Wasi L, He Z . UPK3A: a promising novel urinary marker for the detection of bladder cancer. Urology. 2010; 76(2):514.e6-11. DOI: 10.1016/j.urology.2009.11.045. View

16.

Chitalia V, Foy R, Bachschmid M, Zeng L, Panchenko M, Zhou M . Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol. 2008; 10(10):1208-16. PMC: 2830866. DOI: 10.1038/ncb1781. View

17.

Rui X, Shao S, Wang L, Leng J . Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram. BMC Cancer. 2019; 19(1):1179. PMC: 6892211. DOI: 10.1186/s12885-019-6391-9. View

18.

Lamy P, Allory Y, Gauchez A, Asselain B, Beuzeboc P, de Cremoux P . Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. Eur Urol Focus. 2017; 4(6):790-803. DOI: 10.1016/j.euf.2017.02.017. View

19.

Dominiak A, Chelstowska B, Olejarz W, Nowicka G . Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions. Cancers (Basel). 2020; 12(5). PMC: 7281160. DOI: 10.3390/cancers12051232. View

20.

Kang K, Ryu Y, Piao M, Shilnikova K, Kang H, Yi J . DUOX2-mediated production of reactive oxygen species induces epithelial mesenchymal transition in 5-fluorouracil resistant human colon cancer cells. Redox Biol. 2018; 17:224-235. PMC: 6006906. DOI: 10.1016/j.redox.2018.04.020. View